Proton radiation with immunotherapy for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining proton beam radiation with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer (HCC) that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (HCC) that is too advanced for surgery or transplant.
- Your liver tumors measure less than 20 cm total, with no single tumor larger than 15 cm.
- You are 18 years or older and have a good performance status (ECOG 0 or 1).
- Your liver function is well preserved (Child-Pugh score 5 or 6) and blood counts are adequate.
- You do not have active hepatitis B or C, or other serious health conditions like active infections, bleeding disorders, or autoimmune diseases.
- You have not had prior radiation or certain therapies to the liver area, and all tumor sites can be treated with proton radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests a new combination for liver cancer that has not responded to one earlier treatment. It uses a focused type of radiation (SBRT) plus an immunotherapy drug called QL1706 (a medicine that helps your immune system attack cancer). The goal is to see if this combination can control the cancer better.
This trial tests a combination of radiation therapy, an immunotherapy drug (tislelizumab), and a targeted therapy drug (anlotinib) for people with liver cancer that has spread into the main blood vessel of the liver (portal vein). The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus targeted proton radiation for liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors and improve outcomes for people with intermediate or advanced stage liver cancer.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial studies how radiation therapy affects the immune system and outcomes in people with liver cancer. It may help doctors understand better ways to treat the disease.
Hear when a new Durvalumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.